Factor-inhibiting HIF-1 (FIH-1) is required for human vascular endothelial cell survival

FASEB Journal

Volumn 29, Issue 7, 2015, Pages 2814-2827

  Kiriakidis, Serafim ^a   Henze, Anne Theres ^b,c   Kruszynska Ziaja, Ilona ^a   Skobridis, Konstantinos ^d   Theodorou, Vassiliki ^d   Paleolog, Ewa M ^a   Mazzone, Massimiliano ^b,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Angiogenesis; Apoptosis; Notch2

Indexed keywords

FACTOR INHIBITING HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1; NOTCH2 RECEPTOR; SURVIVIN; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; BIRC5 PROTEIN, HUMAN; CELL CYCLE PROTEIN; HEY1 PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; HIF1AN PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INHIBITOR OF APOPTOSIS PROTEIN; MESSENGER RNA; MIXED FUNCTION OXIDASE; NOTCH2 PROTEIN, HUMAN; REPRESSOR PROTEIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; ANTAGONISTS AND INHIBITORS; CELL HYPOXIA; CYTOLOGY; GENE SILENCING; GENETICS; METABOLISM; UMBILICAL VEIN ENDOTHELIAL CELL;

APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL CYCLE PROTEINS; CELL HYPOXIA; CELL PROLIFERATION; CELL SURVIVAL; ENDOTHELIAL CELLS; GENE KNOCKDOWN TECHNIQUES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INHIBITOR OF APOPTOSIS PROTEINS; MIXED FUNCTION OXYGENASES; RECEPTOR, NOTCH2; REPRESSOR PROTEINS; RNA INTERFERENCE; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84940108156     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.14-252379     Document Type: Article

References (54)

1. Mahon, P. C., Hirota, K., and Semenza, G. L. (2001) FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15, 2675-2686
2. Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J., and Whitelaw, M. L. (2002) Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295, 858-861
3. Hewitson, K. S., McNeill, L. A., Riordan, M. V., Tian, Y. M., Bullock, A. N., Welford, R. W., Elkins, J. M., Oldham, N. J., Bhattacharya, S., Gleadle, J. M., Ratcliffe, P. J., Pugh, C. W., and Schofield, C. J. (2002) Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J. Biol. Chem. 277, 26351-26355
4. Semenza, G. L. (2009) Regulationofoxygen homeostasisbyhypoxiainducible factor 1. Physiology (Bethesda) 24, 97-106
5. Semenza, G. L. (2010) Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29, 625-634
6. Carmeliet, P., and Jain, R. K. (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298-307
7. Konisti, S., Kiriakidis, S., and Paleolog, E. M. (2012) Hypoxia-a key regulator of angiogenesis and inflammation in rheumatoid arthritis. Nat. Rev. Rheumatol. 8, 153-162
8. Epstein, A. C., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., Tian, Y. M., Masson, N., Hamilton, D. L., Jaakkola, P., Barstead, R., Hodgkin, J., Maxwell, P. H., Pugh, C. W., Schofield, C. J., and Ratcliffe, P. J. (2001) C.elegansEGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107, 43-54
9. Maxwell, P. H., Wiesener, M. S., Chang, G. W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., and Ratcliffe, P. J. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275
10. Tanimoto, K., Makino, Y., Pereira, T., and Poellinger, L. (2000) Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. 19, 4298-4309
11. Bruick, R. K., and McKnight, S. L. (2001) A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294, 1337-1340
12. Hon, W. C., Wilson, M. I., Harlos, K., Claridge, T. D., Schofield, C. J., Pugh, C. W., Maxwell, P. H., Ratcliffe, P. J., Stuart, D. I., and Jones, E. Y. (2002) Structural basis for the recognition ofhydroxyproline in HIF-1 alpha by pVHL. Nature 417, 975-978
13. Koivunen, P., Hirsilä, M., Günzler, V., Kivirikko, K. I., and Myllyharju, J. (2004) Catalytic properties ofthe asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J. Biol. Chem. 279, 9899-9904
14. Stolze, I. P., Tian, Y. M., Appelhoff, R. J., Turley, H., Wykoff, C. C., Gleadle, J. M., and Ratcliffe, P. J. (2004) Genetic analysisofthe role of the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor (FIH) in regulating hypoxia-inducible factor (HIF) transcriptional target genes [corrected]. J. Biol. Chem. 279, 42719-42725
15. Tian, Y. M., Yeoh, K. K., Lee, M. K., Eriksson, T., Kessler, B. M., Kramer, H. B., Edelmann, M. J., Willam, C., Pugh, C. W., Schofield, C. J., and Ratcliffe, P. J. (2011) Differential sensitivity of hypoxia inducible factor hydroxylation sites to hypoxia and hydroxylase inhibitors. J. Biol. Chem. 286, 13041-13051
16. Cockman, M. E., Lancaster, D. E., Stolze, I. P., Hewitson, K. S., McDonough, M. A., Coleman, M. L., Coles, C. H., Yu, X., Hay, R. T., Ley, S. C., Pugh, C. W., Oldham, N. J., Masson, N., Schofield, C. J., and Ratcliffe, P. J. (2006) Posttranslational hydroxylation of ankyrin repeats in IkappaB proteins by the hypoxia-inducible factor (HIF) asparaginyl hydroxylase, factor inhibiting HIF (FIH). Proc. Natl. Acad. Sci. USA 103, 14767-14772
17. Zheng, X., Linke, S., Dias, J. M., Zheng, X., Gradin, K., Wallis, T. P., Hamilton, B. R., Gustafsson, M., Ruas, J. L., Wilkins, S., Bilton, R. L., Brismar, K., Whitelaw, M. L., Pereira, T., Gorman, J. J., Ericson, J., Peet, D. J., Lendahl, U., and Poellinger, L. (2008) Interaction with factor inhibiting HIF-1 defines an additional mode of cross-coupling between the Notch and hypoxia signaling pathways. Proc. Natl. Acad. Sci. USA 105, 3368-3373
18. Cockman, M. E., Webb, J. D., and Ratcliffe, P. J. (2009) FIH-dependent asparaginyl hydroxylation of ankyrin repeat domaincontaining proteins. Ann. N. Y. Acad. Sci. 1177, 9-18
19. Khan, M. N., Bhattacharyya, T., Andrikopoulos, P., Esteban, M. A., Barod, R., Connor, T., Ashcroft, M., Maxwell, P. H., and Kiriakidis, S. (2011) Factor inhibiting HIF (FIH-1) promotes renal cancer cell survival by protecting cells from HIF-1α-mediated apoptosis. Br. J. Cancer 104, 1151-1159
20. Pelletier, J., Dayan, F., Durivault, J., Ilc, K., Pécou, E., Pouysségur, J., and Mazure, N. M. (2012) The asparaginyl hydroxylase factorinhibiting HIF is essential for tumor growth through suppression of the p53-p21 axis. Oncogene 31, 2989-3001
21. Lawson, N. D., Vogel, A. M., and Weinstein, B. M. (2002) Sonic hedgehogandvascular endothelial growthfactor act upstreamofthe Notch pathway during arterial endothelial differentiation. Dev. Cell 3, 127-136
22. Leslie, J. D., Ariza-McNaughton, L., Bermange, A. L., McAdow, R., Johnson, S. L., and Lewis, J. (2007) Endothelial signalling by the Notch ligand Delta-like 4 restricts angiogenesis. Development 134, 839-844
23. Kume, T. (2009) Novel insights into the differential functions of Notch ligands in vascular formation. J. Angiogenes. Res. 1, 8
24. Grosjean, J., Kiriakidis, S., Reilly, K., Feldmann, M., and Paleolog, E. (2006) Vascular endothelial growth factor signalling in endothelial cell survival: a role for NFkappaB. Biochem. Biophys. Res. Commun. 340, 984-994
25. Livak, K. J., and Schmittgen, T. D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2 (2Delta Delta C (T)) method. Methods 25, 402-408
26. Fischer, C., Jonckx, B., Mazzone, M., Zacchigna, S., Loges, S., Pattarini, L., Chorianopoulos, E., Liesenborghs, L., Koch, M., De Mol, M., Autiero, M., Wyns, S., Plaisance, S., Moons, L., van Rooijen, N., Giacca, M., Stassen, J. M., Dewerchin, M., Collen, D., and Carmeliet, P. (2007) Anti-PlGF inhibits growth of VEGF (R) - inhibitor-resistant tumors without affecting healthy vessels. Cell 131, 463-475
27. Larsen, H., Muz, B., Khong, T. L., Feldmann, M., and Paleolog, E. M. (2012) Differential effects of Th1 versus Th2 cytokines in combination with hypoxia on HIFs and angiogenesis in RA. Arthritis Res. Ther. 14, R180
28. Muz, B., Larsen, H., Madden, L., Kiriakidis, S., and Paleolog, E. M. (2012) Prolyl hydroxylase domain enzyme 2 is the major player in regulating hypoxicresponsesinrheumatoidarthritis. Arthritis Rheum. 64, 2856-2867
29. Tran, J., Rak, J., Sheehan, C., Saibil, S. D., LaCasse, E., Korneluk, R. G., and Kerbel, R. S. (1999) Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem. Biophys. Res. Commun. 264, 781-788
30. Mesri, M., Morales-Ruiz, M., Ackermann, E. J., Bennett, C. F., Pober, J. S., Sessa, W. C., and Altieri, D. C. (2001) Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am. J. Pathol. 158, 1757-1765
31. O'Connor, D. S., Schechner, J. S., Adida, C., Mesri, M., Rothermel, A. L., Li, F., Nath, A. K., Pober, J. S., and Altieri, D. C. (2000) Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am. J. Pathol. 156, 393-398
32. Quillard, T., Devalliere, J., Chatelais, M., Coulon, F., Séveno, C., Romagnoli, M., Barillé Nion, S., and Charreau, B. (2009) Notch2 signaling sensitizes endothelial cells to apoptosis by negatively regulating the key protective molecule survivin. PLoS ONE 4, e8244
33. Coleman, M. L., McDonough, M. A., Hewitson, K. S., Coles, C., Mecinovic, J., Edelmann, M., Cook, K. M., Cockman, M. E., Lancaster, D. E., Kessler, B. M., Oldham, N. J., Ratcliffe, P. J., and Schofield, C. J. (2007) Asparaginyl hydroxylation of the Notch ankyrin repeat domain by factor inhibiting hypoxia-inducible factor. J. Biol. Chem. 282, 24027-24038
34. McDonough, M. A., McNeill, L. A., Tilliet, M., Papamicaël, C. A., Chen, Q. Y., Banerji, B., Hewitson, K. S., and Schofield, C. J. (2005) Selective inhibition of factor inhibiting hypoxia-inducible factor. J. Am. Chem. Soc. 127, 7680-7681
35. Mazzone, M., Dettori, D., Leite de Oliveira, R., Loges, S., Schmidt, T., Jonckx, B., Tian, Y. M., Lanahan, A. A., Pollard, P., Ruiz de Almodovar, C., De Smet, F., Vinckier, S., Aragonés, J., Debackere, K., Luttun, A., Wyns, S., Jordan, B., Pisacane, A., Gallez, B., Lampugnani, M. G., Dejana, E., Simons, M., Ratcliffe, P., Maxwell, P., and Carmeliet, P. (2009) Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136, 839-851
36. Coulon, C., Georgiadou, M., Roncal, C., De Bock, K., Langenberg, T., and Carmeliet, P. (2010) From vessel sprouting to normalization: role of the prolyl hydroxylase domain protein/hypoxia-inducible factor oxygen-sensing machinery. Arterioscler. Thromb. Vasc. Biol. 30, 2331-2336
37. Casazza, A., Di Conza, G., Wenes, M., Finisguerra, V., Deschoemaeker, S., and Mazzone, M. (2014) Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment. Oncogene 33, 1743-1754
38. Ferguson III, J. E., Wu, Y., Smith, K., Charles, P., Powers, K., Wang, H., and Patterson, C. (2007) ASB4 is a hydroxylation substrate of FIH and promotes vascular differentiation via an oxygen-dependent mechanism. Mol. Cell. Biol. 27, 6407-6419
39. Cockman, M. E., Webb, J. D., Kramer, H. B., Kessler, B. M., and Ratcliffe, P. J. (2009) Proteomics-based identification of novel factor inhibiting hypoxia-inducible factor (FIH) substrates indicates widespread asparaginyl hydroxylation of ankyrin repeat domaincontaining proteins. Mol. Cell. Proteomics 8, 535-546
40. Fulda, S., and Vucic, D. (2012) Targeting IAP proteins for therapeutic interventionincancer. Nat. Rev. Drug Discov. 11, 109-124
41. Altieri, D. C. (2013) Targeting survivin in cancer. Cancer Lett. 332, 225-228.
42. Zwerts, F., Lupu, F., De Vriese, A., Pollefeyt, S., Moons, L., Altura, R. A., Jiang, Y., Maxwell, P. H., Hill, P., Oh, H., Rieker, C., Collen, D., Conway, S. J., and Conway, E. M. (2007) Lack of endothelial cell survivin causes embryonic defects in angiogenesis, cardiogenesis, and neural tube closure. Blood 109, 4742-4752
43. Wilkins, S. E., Hyvärinen, J., Chicher, J., Gorman, J. J., Peet, D. J., Bilton, R. L., and Koivunen, P. (2009) Differences in hydroxylation and binding of Notch and HIF-1alpha demonstrate substrate selectivity for factor inhibiting HIF-1 (FIH-1). Int. J. Biochem. Cell Biol. 41, 1563-1571
44. Wilkins, S. E., Karttunen, S., Hampton-Smith, R. J., Murchland, I., Chapman-Smith, A., and Peet, D. J. (2012) Factor inhibiting HIF (FIH) recognizes distinct molecular features within hypoxiainducible factor-a (HIF-a) versus ankyrin repeat substrates. J. Biol. Chem. 287, 8769-8781
45. Gridley, T. (2007) Notch signaling in vascular development and physiology. Development 134, 2709-2718
46. Mailhos, C., Modlich, U., Lewis, J., Harris, A., Bicknell, R., and Ish-Horowicz, D. (2001) Delta4, anendothelial specific Notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation 69, 135-144
47. Patel, N. S., Li, J. L., Generali, D., Poulsom, R., Cranston, D. W., and Harris, A. L. (2005) Up-regulation of Delta-like 4 ligand in human tumor vasculatureand the roleofbasal expressioninendothelial cell function. Cancer Res. 65, 8690-8697
48. Hainaud, P., Contrerès, J. O., Villemain, A., Liu, L. X., Plouët, J., Tobelem, G., and Dupuy, E. (2006) The role of the vascular endothelial growth factor-Delta-like 4 ligand/Notch4-ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions. Cancer Res. 66, 8501-8510
49. Quillard, T., Devallière, J., Coupel, S., and Charreau, B. (2010) Inflammation dysregulates Notch signaling in endothelial cells: implication of Notch2 and Notch4 to endothelial dysfunction. Biochem. Pharmacol. 80, 2032-2041
50. Andersson, E. R., Sandberg, R., and Lendahl, U. (2011) Notch signaling: simplicityin design, versatilityinfunction. Development 138, 3593-3612
51. Wang, M. M. (2011) Notch signaling and Notch signaling modifiers. Int. J. Biochem. Cell Biol. 43, 1550-1562
52. Gustafsson, M. V., Zheng, X., Pereira, T., Gradin, K., Jin, S., Lundkvist, J., Ruas, J. L., Poellinger, L., Lendahl, U., and Bondesson, M. (2005) Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev. Cell 9, 617-628
53. Peng, H., Kaplan, N., Hamanaka, R. B., Katsnelson, J., Blatt, H., Yang, W., Hao, L., Bryar, P. J., Johnson, R. S., Getsios, S., Chandel, N. S., and Lavker, R. M. (2012) microRNA-31/factor-inhibiting hypoxiainducible factor 1 nexus regulates keratinocyte differentiation. Proc. Natl. Acad. Sci. USA 109, 14030-14034
54. Zhang, N., Fu, Z., Linke, S., Chicher, J., Gorman, J. J., Visk, D., Haddad, G. G., Poellinger, L., Peet, D. J., Powell, F., and Johnson, R. S. (2010) The asparaginyl hydroxylase factor inhibiting HIF-1alpha is an essential regulator of metabolism. Cell Metab. 11, 364-378